Case report highlights ECMO's role in treating RSV ARDS in an immunocompromised infant, suggesting improved outcomes.
Respiratory syncytial virus (RSV) infection significantly increases morbidity and mortality in immunocompromised patients, especially those undergoing hematopoietic stem cell transplantation (HSCT).Recent advancements in ECMO and HSCT management have improved survival in this population.We present a complex case of a 10-month-old post-HSCT infant who required venoarterial (VA) ECMO support for severe RSV-associated ARDS, highlighting the challenges and strategies in managing immunocompromised children on ECMO.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: